Key result
CRT is linked to an ~11% LVEF improvement at 12 months and reduced ketone bodies.
Why the study?
It was unknown whether CRT improves the systemic metabolomic profile by enhancing left ventricular function in patients with heart failure with reduced LVEF.
Does cardiac resynchronization therapy improve systemic metabolomic profile and left ventricular function in patients with advanced heart failure?
Cohort (n=92)
Does cardiac resynchronization therapy improve systemic metabolomic profile and left ventricular function in patients with advanced heart failure?
Cardiac resynchronization therapy improves left ventricular function and modulates systemic plasma metabolomic profiles, particularly reducing ketone bodies and branched-chain amino acids in nonischemic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
CRT-linked metabolomic shifts in HFrEF may indicate better substrate use; hypothesis-generating for response prediction, needs prospective validation.
BACKGROUND: It is unknown whether cardiac resynchronization therapy (CRT) improves systemic metabolomic profile by enhancing left ventricular function. The observational cohort study aimed to investigate the effect of CRT on left ventricular ejection fraction (LVEF) and circulating plasma metabolites in patients who had heart failure with reduced LVEF. METHODS: We prospectively screened patients with ischemic cardiomyopathy and nonischemic cardiomyopathy who received CRT with a defibrillator for LVEF ≤35% according to current guidelines. Clinical assessment included echocardiography and device interrogation. Blood samples for metabolomic analysis were collected before CRT and at 6-month follow-up. Plasma was subjected to gas chromatography-mass spectrometry and 1 H nuclear magnetic resonance-based metabolomic analysis. RESULTS: Totally 92 patients were enrolled, with a mean age of 67.3±11.3 years (37.0% female). LVEF was significantly improved from 28.9±7.6% at baseline to 36.0±11.3% at 6 months ( P <0.001) and to 40.1±12.6% at 12 months ( P <0.001). After CRT, 42 metabolite features were significantly decreased compared with the baseline. The ketone bodies, including 3-hydroxybutyrate ( P <0.001) and acetone ( P =0.01), were reduced. A branched-chain amino acid, isoleucine, was also decreased after CRT ( P =0.01). These metabolomic changes were mainly observed in the nonischemic cardiomyopathy group, while the metabolomic profile in the ischemic cardiomyopathy group was characterized by enhanced amino acid oxidation and elevated levels of lactate and pyruvate. The improvement in LVEF positively correlated with the ratio of changes in ketone bodies and isoleucine. CONCLUSIONS: CRT may modulate the systemic plasma metabolomic profile, which correlated with improvement in left ventricular function in patients with severe heart failure with reduced ejection fraction.
No takes yet. Share an insight, caveat, or question.
Qian et al. (2026) conducted a cohort in Heart failure with reduced LVEF (n=92). Cardiac resynchronization therapy (CRT) vs. Baseline (pre-CRT) was evaluated on Left ventricular ejection fraction (LVEF) (p=<0.001). Cardiac resynchronization therapy improved LVEF from 28.9% at baseline to 40.1% at 12 months and modulated systemic plasma metabolomic profiles, including reduced ketone bodies.
Synapse has enriched 10 related papers. Consider them for comparative context: